Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Sunlenca“
Suchtreffer
Begriffe & Kennungen
Sunlenca · 4.5 · Strong CYP3A4 inhibitors alone (e.g. voriconazole) or strong inhibitors of CYP3A4 and P-gp together (e.g. cobi
Eintrag öffnenSunlenca · 4.5 · Strong inhibitors of CYP3A, P-gp and UGT1A1 together (i.e., all 3 pathways), such as atazanavir/cobicistat, ma
Eintrag öffnenSunlenca · 4.5 · Table 2: Interactions between Sunlenca and other medicinal products
Eintrag öffnenSunlenca · 4.5 · Table 2: Interactions between Sunlenca and other medicinal products
Eintrag öffnenSunlenca · 4.5 · Tenofovirk: AUC:↑ 47% Cmax:↑ 23%
Eintrag öffnenSunlenca · 4.5 · Tenofovirk: AUC:↑ 47% Cmax:↑ 23% ERGOT DERIVATIVES Dihydroergotamine Interaction not studied. Caution is warra
Eintrag öffnenSunlenca · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenSunlenca · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenSunlenca · 4.8 Undesirable effects · 1
Eintrag öffnenSunlenca · 4.8 Undesirable effects · 2
Eintrag öffnenSunlenca · 4.8 · 26 Reporting of suspected adverse reactions
Eintrag öffnenSunlenca · 4.8 · 9 A tabulated list of adverse reactions is presented in Table 3. Frequencies are defined as very common (≥1/10
Eintrag öffnenSunlenca · 4.8 · Description of selected adverse reactions
Eintrag öffnenSunlenca · 4.8 · Description of selected adverse reactions
Eintrag öffnenSunlenca · 4.8 · Frequencya Adverse reaction Immune system disorders Not known immune reconstitution inflammatory syndrome Gast
Eintrag öffnenSunlenca · 4.8 · Frequencya Adverse reaction Immune system disorders Not known immune reconstitution inflammatory syndrome Gast
Eintrag öffnenSunlenca · 4.8 · Immune Reconstitution Inflammatory Syndrome In patients with HIV with severe immune deficiency at the time of
Eintrag öffnenSunlenca · 4.8 · Immune Reconstitution Inflammatory Syndrome In patients with HIV with severe immune deficiency at the time of
Eintrag öffnenSunlenca · 4.8 · Local injection site reactions Through Week 156 of treatment, most participants had mild (Grade 1, 54%) or mod
Eintrag öffnenSunlenca · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnen